New trial
Phase 2 Trial: Subcutaneous Nivolumab with Ipilimumab and Chemotherapy in Untreated NSCLC
- Trial ID
- NCT06946797 on ClinicalTrials.gov
- Cancer type
- Non-Small Cell Lung Cancer
- Location
- 45 Locations
- Published in
- New in Oncology - May 14, 2025
Bristol-Myers Squibb is evaluating two dosing regimens of subcutaneous nivolumab combined with intravenous ipilimumab and standard chemotherapy in patients with previously untreated metastatic or recurrent NSCLC to optimize efficacy and safety.
More in non-small cell lung cancer
-
Trial result · Oct 22, 2026 · NCT04905316
Canakinumab (IL-1β blockade) + cCRT and durvalumab consolidation hits 67% 24-mo PFS in unresectable stage III NSCLC -
Trial result · Oct 15, 2026 · NCT04495153
CAN-2409 + valacyclovir reports 14.3-month median OS in treated NSCLC patients; 24.5 months in a selected per-protocol group -
New trial · Oct 15, 2026 · NCT07852247
Phase 1 CyberKnife SBRT uses Synchrony respiratory motion tracking for ultra-central NSCLC -
New trial · Oct 15, 2026 · NCT07617337
Phase 1 AQUA07 allosteric ALK inhibitor (macrocyclic peptide) alone or with lorlatinib in ALK-positive NSCLC -
Trial result · Oct 8, 2026 · NCT03052608
AI volumetric brain-met response may better predict PFS in ALK+ NSCLC